MedTrace Logo

A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region

NCT07710664 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-07-17

No results posted yet for this study

Summary

This is an open-label, single-center, investigator-initiated exploratory trial evaluating NWRD09 in 10 participants with persistent HPV16 infection in the anal region.

Conditions

  • Persistent HPV16 Infection

Interventions

DRUG

NWRD09

Each participant will be administered NWRD09 by IM injection

Sponsors & Collaborators

  • Newish Biotech (Wuxi) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pengyuan Wang, MD · Peking University First Hospital

  • Zeyang Chen, MD · Peking University First Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-20
Primary Completion
2026-12-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07710664 on ClinicalTrials.gov